MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Urology

  • Home
  • Specialties
  • Urology
  • Page 2
Salvage Focal Therapy vs. Radical Prostatectomy: Comparable 10-Year Survival with Dramatically Reduced Morbidity
Posted innews Oncology Urology

Salvage Focal Therapy vs. Radical Prostatectomy: Comparable 10-Year Survival with Dramatically Reduced Morbidity

Posted by By MedXY 02/20/2026
A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications for patients with localized radiorecurrent prostate cancer.
Read More
Metastasis-Directed Therapy Delivers Clear Progression Benefits in Oligometastatic Prostate Cancer: The WOLVERINE IPD Meta-Analysis
Posted innews Oncology Urology

Metastasis-Directed Therapy Delivers Clear Progression Benefits in Oligometastatic Prostate Cancer: The WOLVERINE IPD Meta-Analysis

Posted by By MedXY 02/18/2026
The WOLVERINE individual patient data meta-analysis confirms that metastasis-directed therapy significantly improves progression-free and castration resistance-free survival in oligometastatic prostate cancer, providing high-level evidence for a paradigm shift in clinical management.
Read More
Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer
Posted innews Oncology Urology

Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer

Posted by By MedXY 02/09/2026
A retrospective cohort study of 669 veterans suggests that docetaxel rechallenge provides a significant survival benefit compared to cabazitaxel for patients with metastatic castration-resistant prostate cancer who previously responded to docetaxel without disease progression.
Read More
Low Baseline PSA Predicts Exceptional Long-Term Safety: A 20-Year Paradigm Shift in Prostate Cancer Screening
Posted innews Oncology Urology

Low Baseline PSA Predicts Exceptional Long-Term Safety: A 20-Year Paradigm Shift in Prostate Cancer Screening

Posted by By MedXY 02/09/2026
A 20-year cohort study shows that baseline PSA levels in men aged 45-70 are highly predictive of long-term prostate cancer risk, with PSA <1.0 ng/mL indicating a very low 20-year incidence of 3.3%, supporting extended screening intervals for low-risk individuals.
Read More
PGT-A for Severe Male Infertility: Reducing Pregnancy Loss Without Boosting Live Birth Rates
Posted innews Urology

PGT-A for Severe Male Infertility: Reducing Pregnancy Loss Without Boosting Live Birth Rates

Posted by By MedXY 01/22/2026
A multicentre RCT published in the BMJ demonstrates that while PGT-A does not increase cumulative live birth rates for couples with severe male infertility, it significantly reduces the risk of pregnancy loss, providing a nuanced framework for clinical counseling.
Read More
Atezolizumab and BCG Combination Fails to Improve Event-Free Survival in High-Risk NMIBC: Results from the ALBAN Phase III Trial
Posted innews Oncology Urology

Atezolizumab and BCG Combination Fails to Improve Event-Free Survival in High-Risk NMIBC: Results from the ALBAN Phase III Trial

Posted by By MedXY 01/14/2026
The Phase III ALBAN trial found that adding atezolizumab to BCG therapy did not improve event-free survival in BCG-naive high-risk non-muscle-invasive bladder cancer, highlighting the complexity of immune checkpoint inhibitor synergy in this setting.
Read More
Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial
Posted innews Oncology Urology

Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial

Posted by By MedXY 01/13/2026
The MetaCURE trial demonstrates that combining surgery, radiation, and advanced hormonal therapies can achieve deep responses in high-risk prostate cancer, paving the way for faster drug development through intermediate clinical endpoints.
Read More
Integrating Automated Radiomics with Serum Biomarkers Redefines Risk Stratification in Metastatic Castration-Resistant Prostate Cancer
Posted innews Oncology Urology

Integrating Automated Radiomics with Serum Biomarkers Redefines Risk Stratification in Metastatic Castration-Resistant Prostate Cancer

Posted by By MedXY 01/13/2026
This article explores how novel automated imaging tools, combined with clinical biomarkers, enhance risk stratification in mCRPC, while also reviewing the pivotal OS data from abiraterone and enzalutamide trials that inform contemporary treatment standards.
Read More
Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer
Posted innews Oncology Urology

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer

Posted by By MedXY 01/12/2026
A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MSI as a viable alternative for patient selection.
Read More
MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer
Posted innews Oncology Urology

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer

Posted by By MedXY 01/12/2026
A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for patient selection when tissue is limited.
Read More
AHR Inhibition with IK-175: A New Frontier in Overcoming Checkpoint Resistance in Urothelial Carcinoma
Posted innews Oncology Urology

AHR Inhibition with IK-175: A New Frontier in Overcoming Checkpoint Resistance in Urothelial Carcinoma

Posted by By MedXY 01/11/2026
This Phase 1/1b study demonstrates that IK-175, an oral AHR inhibitor, is safe and clinically active in PD-1-refractory urothelial carcinoma, showing target engagement and preliminary efficacy both as monotherapy and in combination with nivolumab.
Read More
The Evolving Paradigm in High-Risk NMIBC: Critical Synthesis of Checkpoint Inhibitors and BCG Combination Therapy
Posted innews Oncology Urology

The Evolving Paradigm in High-Risk NMIBC: Critical Synthesis of Checkpoint Inhibitors and BCG Combination Therapy

Posted by By MedXY 01/10/2026
A comprehensive meta-analysis of the POTOMAC, CREST, and ALBAN trials reveals that adding PD-(L)1 inhibitors to BCG improves event-free survival in high-risk NMIBC. However, increased toxicity and agent-specific variations in efficacy suggest a need for cautious, individualized clinical adoption.
Read More
Shifting the Paradigm: Noncontrast MRI-First Screening Strategy Significantly Increases Detection of Clinically Significant Prostate Cancer
Posted innews Radiology Urology

Shifting the Paradigm: Noncontrast MRI-First Screening Strategy Significantly Increases Detection of Clinically Significant Prostate Cancer

Posted by By MedXY 01/10/2026
The PROSA trial reveals that a contrast-free biparametric MRI-first screening approach doubles the detection of clinically significant prostate cancer compared to PSA-triggered pathways, while maintaining favorable cost-effectiveness and benefit-harm ratios.
Read More
Molecular Imaging and PET-Guided Dose Escalation Revolutionize Salvage Radiotherapy: Insights from EMPIRE-1 and EMPIRE-2
Posted innews Oncology Urology

Molecular Imaging and PET-Guided Dose Escalation Revolutionize Salvage Radiotherapy: Insights from EMPIRE-1 and EMPIRE-2

Posted by By MedXY 01/10/2026
The EMPIRE trials demonstrate that integrating molecular imaging and PET-guided dose escalation significantly improves event-free survival in patients requiring salvage radiotherapy for prostate cancer recurrence.
Read More
Multimodal AI Outperforms Clinical Nomograms in Predicting Metastasis for Post-Prostatectomy Biochemical Recurrence
Posted inAI news Oncology Urology

Multimodal AI Outperforms Clinical Nomograms in Predicting Metastasis for Post-Prostatectomy Biochemical Recurrence

Posted by By MedXY 01/10/2026
A validated multimodal AI model using digital pathology and clinical data significantly improves risk stratification for prostate cancer patients with biochemical recurrence, identifying those who derive the greatest benefit from salvage hormone therapy.
Read More
Audit and Feedback in NMIBC Surgery: Improved Documentation Does Not Translate to Better Clinical Outcomes
Posted innews Oncology Urology

Audit and Feedback in NMIBC Surgery: Improved Documentation Does Not Translate to Better Clinical Outcomes

Posted by By MedXY 01/10/2026
A global cluster randomized trial (RESECT) demonstrates that while audit and feedback improve surgical documentation in non-muscle-invasive bladder cancer, they fail to enhance detrusor muscle sampling, adjuvant chemotherapy use, or early recurrence rates.
Read More
The NanoKnife Revolution: A Non-Thermal Leap Forward in Precision Prostate Cancer Care
Posted innews Oncology Urology

The NanoKnife Revolution: A Non-Thermal Leap Forward in Precision Prostate Cancer Care

Posted by By MedXY 01/10/2026
The PRESERVE trial demonstrates that Irreversible Electroporation (IRE) using the NanoKnife System is a safe and effective focal therapy for intermediate-risk prostate cancer, offering high success rates while preserving urinary and sexual health.
Read More
Stockholm3 Versus PSA in Prostate Cancer Screening: A Synthesis of 9-year Outcomes, Repeat Screening, and Multiethnic Validation
Posted inClinical Updates news Oncology Urology

Stockholm3 Versus PSA in Prostate Cancer Screening: A Synthesis of 9-year Outcomes, Repeat Screening, and Multiethnic Validation

Posted by By MedXY 01/09/2026
This review synthesizes long-term outcomes and multiethnic data demonstrating that the Stockholm3 test significantly improves the detection of aggressive prostate cancer while reducing overdiagnosis and unnecessary procedures compared to traditional PSA-based screening.
Read More
Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC
Posted innews Oncology Urology

Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC

Posted by By MedXY 01/09/2026
The CAPItello-281 trial shows that capivasertib plus abiraterone improves radiographic progression-free survival by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer, highlighting the importance of biomarker-driven therapy.
Read More
Integrating Local and Metastasis-Directed Therapies Redefines Survival in Oligometastatic Prostate Cancer: Evidence from an Umbrella Review
Posted innews Oncology Urology

Integrating Local and Metastasis-Directed Therapies Redefines Survival in Oligometastatic Prostate Cancer: Evidence from an Umbrella Review

Posted by By MedXY 01/08/2026
An umbrella review of 21 meta-analyses involving 160,000 patients confirms that prostate radiotherapy and metastasis-directed therapy significantly improve survival and progression control in oligometastatic prostate cancer, establishing a new multimodal standard of care.
Read More

Posts pagination

Previous page 1 2 3 4 … 8 Next page
  • Carotid Artery Stenting Emerges as a Proven Adjunct to Intensive Medical Therapy in Stroke Prevention: Insights from CREST-2
  • Korsakoff Syndrome: Clinical Profiles, Brain Imaging Insights, and Mortality Risks in a Large Cohort
  • IVIG Plus Prednisone Enhances Recovery in Newly Diagnosed Idiopathic Inflammatory Myopathies: Insights from a Randomized Clinical Trial
  • Differential Physical Activity Responses to Diabetes Risk Reduction Interventions According to Prediabetes Phenotype: Insights from Pooled Randomized Controlled Trials
  • Social Inequalities in Gestational Diabetes: Insights from a Nationwide Swedish Cohort Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top